Jorgen Radke
Overview
Explore the profile of Jorgen Radke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mager K, Wehner R, Bahr F, Oelschlagel U, Platzbecker U, Wermke M, et al.
Transplantation
. 2012 May;
93(12):1270-5.
PMID: 22643330
Background: Infections and acute graft-versus-host disease (GvHD) represent major complications of allogeneic stem-cell transplantation (SCT). Dendritic cells (DCs) display an extraordinary capacity to induce innate and adaptive immune responses. Therefore,...
2.
Sockel K, Wermke M, Radke J, Kiani A, Schaich M, Bornhauser M, et al.
Haematologica
. 2011 Jul;
96(10):1568-70.
PMID: 21750085
No abstract available.
3.
Stolzel F, Rollig C, Radke J, Mohr B, Platzbecker U, Bornhauser M, et al.
Haematologica
. 2011 Jun;
96(10):1552-6.
PMID: 21685468
Myeloid sarcoma in acute myeloid leukemia has been clearly defined by the World Health Organization but studies regarding the prevalence and the prognostic impact of extramedullary acute myeloid leukemia have...
4.
Bornhauser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, et al.
Blood
. 2011 May;
117(26):7174-84.
PMID: 21540460
Donor lymphocyte infusions have been effective in patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation, but their use is associated with the risk of graft-versus-host disease....
5.
Lauter A, Strumpf A, Platzbecker U, Schetelig J, Wermke M, Radke J, et al.
Br J Haematol
. 2009 Dec;
148(6):910-7.
PMID: 19995390
The addition of radioimmunotherapy to conventional and reduced-intensity conditioning has been shown to be feasible and effective. Within an ongoing prospective phase II trial, 22 patients with advanced myeloid malignancies...
6.
von Bonin M, Hochauf K, Monecke S, Radke J, Thiede C, Bornhauser M, et al.
Leuk Res
. 2009 Mar;
33(7):e88-90.
PMID: 19307017
No abstract available.
7.
Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, et al.
Biol Blood Marrow Transplant
. 2009 Jan;
15(1):101-8.
PMID: 19135948
A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia...
8.
von Bonin M, Oelschlagel U, Radke J, Stewart M, Ehninger G, Bornhauser M, et al.
Transplantation
. 2008 Sep;
86(6):875-9.
PMID: 18813113
Rituximab, an anti-CD20 chimeric monoclonal antibody, is widely used in hematologic malignancies and has been introduced as a therapeutic option in autoimmune disorders. In recent studies, rituximab has shown promising...
9.
Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler U, Mohr B, et al.
Ann Hematol
. 2003 Dec;
83(6):401-2.
PMID: 14673623
Imatinib mesylate (STI571) is a very effective treatment option for Ph(+) chronic myeloid leukemia (CML) in chronic phase. Secondary treatment failures have mostly been observed in patients with advanced stages...